PHENOTARGET BIOSCIENCES INC

ESCONDIDO, CA · Biotech · Private

Cyclic peptide-based antiviral therapeutics discovered via molecular evolution technology targeting SARS-CoV-2 and viral protein-protein interactions

Grants
$255K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase I · STTR Phase I: Discovery and Development of Macrocyclic Peptide Inhibitors of SARS-COV-2 Spike Protein for the Treatment of COVID-19$255,473
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2963PAPIVAX, LLC——
2964Nutriforward, LLC——
2965Regenicin, Inc.—$4.5M
2966PHENOTARGET BIOSCIENCES INC——
296742Bio, LLC——
2968ReNeuroGen LLC——
2969The NanoMedicines Innovation Network——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.